{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:55:46Z","timestamp":1781636146038,"version":"3.54.5"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anthracyclines are routinely used in pediatric oncology but cause dose-dependent cardiotoxicity that compromises long-term survival. Neurohormonal agents such as ACE inhibitors (ACEi), angiotensin receptor blockers (ARBs), and beta-blockers have been suggested as preventive or therapeutic agents, yet evidence in children remains limited. Present review aimed to synthesize available data on their efficacy and safety among this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Scopus, and Web of Science was conducted from inception to August 2025. Eligible studies included pediatric cancer survivors exposed to anthracyclines who received ACEi, ARBs, or beta-blockers with reported cardiac outcomes. Data extraction and risk-of-bias assessments were performed independently by two reviewers. Findings were synthesized narratively owing to study heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Sixteen studies met inclusion criteria, comprising nine RCTs, three observational studies, two case series, and two case reports. ACEi, mainly enalapril and captopril, were associated with attenuation of left ventricular ejection fraction (LVEF) decline and reduced biomarker elevations, although long-term benefits were inconsistent and side effects such as hypotension were reported. Beta-blockers, particularly carvedilol, improved ventricular function, strain indices, and clinical symptoms in several studies, though the largest trial (PREVENT-HF) did not show significant benefit on primary remodeling outcomes, except in high-risk subgroups. Overall, the evidence suggests that while preventive use of ACEi\/ARBs and beta-blockers shows more consistent benefits, findings regarding their role in reversing established cardiotoxicity remain variable and should be interpreted cautiously.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ACEi\/ARBs and beta-blockers showed promise in preventing or mitigating anthracycline-induced cardiotoxicity among children, with consistent benefits on surrogate outcomes but uncertain durability and survival impact. Early initiation and targeted use in high-risk patients appear most advantageous, underscoring the need for large biomarker-guided trials to refine prevention strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40959-026-00447-5","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:14:19Z","timestamp":1771420459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardioprotective strategies of ACEi\/ARBs and beta-blockers against anthracycline-induced cardiotoxicity in pediatric cancer survivors: a systematic review"],"prefix":"10.1186","volume":"12","author":[{"given":"Reza","family":"Sattarpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Noori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"447_CR1","doi-asserted-by":"crossref","unstructured":"Laz\u01cer DR, Farca\u015f AD, Blag C, Neaga A, Zdrenghea MT, C\u01ceinap C, et al. Cardiotoxicity: a major setback in childhood leukemia treatment. Dis Markers. 2021;2021:8828410.","DOI":"10.1155\/2021\/8828410"},{"key":"447_CR2","doi-asserted-by":"crossref","unstructured":"Fraley C, Milgrom SA, Kondapalli L, Taylor MRG, Mestroni L, Miyamoto SD. Mechanisms and insights for the development of heart failure associated with cancer therapy. Children. 2021;8(9).","DOI":"10.3390\/children8090829"},{"issue":"3","key":"447_CR3","first-page":"217","volume":"156","author":"R Rivas-Ruiz","year":"2020","unstructured":"Rivas-Ruiz R, Ure\u00f1a-Wong K, Castel\u00e1n-Mart\u00ednez OD, Betanzos-Cabrera Y, Lazo-C\u00e1rdenas C, Ram\u00edrez-Portillo C, et al. Predictors of anthracycline-induced cardiotoxicity in a retro-prolective cohort of children surviving cancer. Gac Med Mex. 2020;156(3):217\u201323.","journal-title":"Gac Med Mex"},{"key":"447_CR4","doi-asserted-by":"crossref","unstructured":"Tan VZZ, Chan NM, Ang WL, Mya SN, Chan MY, Chen CK. Cardiotoxicity after anthracycline chemotherapy for childhood cancer in a multiethnic Asian population. Front Pead. 2021;9.","DOI":"10.3389\/fped.2021.639603"},{"issue":"Supplement 1","key":"447_CR5","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.1182\/blood-2023-178358","volume":"142","author":"R Khedr","year":"2023","unstructured":"Khedr R, Gaber P, Selim Zs ES. Cardiotoxicity related mortality among children with acute myeloid leukemia in low middle income countries: is it treatment or sepsis related? Blood. 2023;142(Supplement 1):5831.","journal-title":"Blood"},{"issue":"1","key":"447_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2174\/1574885514666190311145607","volume":"15","author":"M Behrouzian","year":"2019","unstructured":"Behrouzian M, Najibi B, Haghi S, Mahdavi C, Jaseb K, Ghaedi E. Prevalence of major cardiac events of Anthracycline-Induced cardiotoxicity in Southwestern iran: different response patterns to cumulative dose. Curr Drug Therapy. 2019;15(1):78\u201384.","journal-title":"Curr Drug Therapy"},{"issue":"11","key":"447_CR7","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1080\/14779072.2021.2013811","volume":"19","author":"N Bansal","year":"2021","unstructured":"Bansal N, Joshi C, Adams MJ, Hutchins K, Ray A, Lipshultz SE. Cardiotoxicity in pediatric lymphoma survivors. Expert Rev Cardiovasc Ther. 2021;19(11):957\u201374.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"2","key":"447_CR8","first-page":"133","volume":"28","author":"LE Radu","year":"2020","unstructured":"Radu LE, Sfetea RC, Arion CV, Colita A. Cardiotoxicity - the first cause of morbidity and mortality in pediatric patients survivors of acute lymphoblastic leukemia. Revista Romana De Med De Laborator. 2020;28(2):133\u201344.","journal-title":"Revista Romana De Med De Laborator"},{"issue":"8","key":"447_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/17425255.2017.1351547","volume":"13","author":"N Bansal","year":"2017","unstructured":"Bansal N, Amdani S, Lipshultz ER, Lipshultz SE. Chemotherapy-induced cardiotoxicity in children. Expert Opin Drug Metabolism Toxicol. 2017;13(8):817\u201332.","journal-title":"Expert Opin Drug Metabolism Toxicol"},{"issue":"1","key":"447_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-025-00332-7","volume":"11","author":"R Liu","year":"2025","unstructured":"Liu R, Fan C, Liu X, Li M, Zhang Y, Zhang M. Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis. Cardio-Oncology. 2025;11(1):1\u201318.","journal-title":"Cardio-Oncology"},{"key":"447_CR11","doi-asserted-by":"crossref","unstructured":"Spadafora L, Muro FMD, Intonti C, Massa L, Monelli M, Franco R, et al. Lifestyle and pharmacological interventions to prevent anthracycline-related cardiotoxicity in cancer patients. J Cardiovasc Dev Dis. 2025;12(6).","DOI":"10.3390\/jcdd12060212"},{"key":"447_CR12","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372.","DOI":"10.1136\/bmj.n71"},{"key":"447_CR13","doi-asserted-by":"crossref","unstructured":"Armenian S, Hudson MM, Lindenfeld L, Chen S, Chow EJ, Colan S et al. Carvedilol for prevention of heart failure in anthracycline-exposed survivors of childhood cancer: results from COG ALTE1621. J Clin Oncol. 2023;41(16).","DOI":"10.1200\/JCO.2023.41.16_suppl.10013"},{"issue":"5","key":"447_CR14","first-page":"791","volume":"6","author":"SH Armenian","year":"2024","unstructured":"Armenian SH, Hudson MM, Lindenfeld L, Chen ST, Chow EJ, Colan S, et al. Carvedilol to improve cardiac remodeling in Anthracycline-Exposed childhood cancer survivors. Jacc: Cardiooncology. 2024;6(5):791\u20133.","journal-title":"Jacc: Cardiooncology"},{"key":"447_CR15","unstructured":"Caffrey M. Carvedilol improves biomarker linked to heart health in survivors of childhood cancer. Am J Managed Care. 2024;30(2)."},{"issue":"Supplement6","key":"447_CR16","first-page":"suaf083","volume":"27","author":"Z Selim","year":"2025","unstructured":"Selim Z, Gouda H, Albeltagi D, Mosaad M, Abdelmassih A, Kamal M, et al. Revisiting the role of angiotensin-converting enzyme inhibitors in preventing chemotherapy cancer related cardiac disease in paediatric malignant bone tumours patients. Eur Heart J Supplements. 2025;27(Supplement6):suaf083.","journal-title":"Eur Heart J Supplements"},{"issue":"6","key":"447_CR17","doi-asserted-by":"publisher","first-page":"S188","DOI":"10.1016\/j.cardfail.2005.06.371","volume":"11","author":"R Agarwal","year":"2005","unstructured":"Agarwal R, Tong A, Yusuf SW, Wells R, Jaffe N, Burrer N, et al. Carvedilol for anthracylcine-induced heart failure in pediatric oncology patients. J Card Fail. 2005;11(6):S188\u2013S.","journal-title":"J Card Fail"},{"issue":"2","key":"447_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1470-2045(23)00637-X","volume":"25","author":"SH Armenian","year":"2024","unstructured":"Armenian SH, Hudson MM, Lindenfeld L, Chen S, Chow EJ, Colan S, et al. Effect of carvedilol versus placebo on cardiac function in anthracycline-exposed survivors of childhood cancer (PREVENT-HF): a randomised, controlled, phase 2b trial. Lancet Oncol. 2024;25(2):235\u201345.","journal-title":"Lancet Oncol"},{"issue":"5","key":"447_CR19","first-page":"791","volume":"6","author":"SH Armenian","year":"2024","unstructured":"Armenian SH, Hudson MM, Lindenfeld L, Chen S, Chow EJ, Colan S, et al. Carvedilol to improve cardiac remodeling in Anthracycline-Exposed childhood cancer survivors: subgroup analysis of COG ALTE1621. JACC: CardioOncology. 2024;6(5):791\u20133.","journal-title":"JACC: CardioOncology"},{"issue":"8","key":"447_CR20","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.cardfail.2012.06.416","volume":"18","author":"NA El-Shitany","year":"2012","unstructured":"El-Shitany NA, Tolba OA, El-Shanshory MR, El-Hawary EE. Protective effect of carvedilol on Adriamycin-Induced left ventricular dysfunction in children with acute lymphoblastic leukemia. J Card Fail. 2012;18(8):607\u201313.","journal-title":"J Card Fail"},{"issue":"11","key":"447_CR21","doi-asserted-by":"publisher","first-page":"e27308","DOI":"10.1002\/pbc.27308","volume":"65","author":"V Gupta","year":"2018","unstructured":"Gupta V, Kumar Singh S, Agrawal V, Bali Singh T. Role of ACE inhibitors in anthracycline-induced cardiotoxicity: A randomized, double-blind, placebo-controlled trial. Pediatr Blood Cancer. 2018;65(11):e27308.","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"447_CR22","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s00246-018-1910-z","volume":"39","author":"JK Harrington","year":"2018","unstructured":"Harrington JK, Richmond ME, Fein AW, Kobsa S, Satwani P, Shah A. Two-Dimensional speckle tracking Echocardiography-Derived strain measurements in survivors of childhood cancer on angiotensin converting enzyme Inhibition or receptor Blockade. Pediatr Cardiol. 2018;39(7):1404\u201312.","journal-title":"Pediatr Cardiol"},{"issue":"5","key":"447_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s004310051294","volume":"159","author":"M Hauser","year":"2000","unstructured":"Hauser M, Wilson N. Anthracycline induced cardiomyopathy: successful treatment with angiotensin converting enzyme inhibitors. Eur J Pediatrics. 2000;159(5):389.","journal-title":"Eur J Pediatrics"},{"issue":"23","key":"447_CR24","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1200\/JCO.2002.12.102","volume":"20","author":"SE Lipshultz","year":"2002","unstructured":"Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC, Shaikh SL, Mone SM, et al. Long-term Enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002;20(23):4517\u201322.","journal-title":"J Clin Oncol"},{"key":"447_CR25","doi-asserted-by":"crossref","unstructured":"Lo SH, Liu YC, Dai ZK, Chen IC, Wu YH, Hsu JH. Case report: low dose of Valsartan\/Sacubitril leads to successful reversal of acute heart failure in Chemotherapy-Induced cardiomyopathy. Front Pead. 2021;9.","DOI":"10.3389\/fped.2021.639551"},{"key":"447_CR26","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/eurheartj\/ehn030","volume":"29","author":"C Mandric","year":"2008","unstructured":"Mandric C, Dimitriu AG, Miron I, Dimitriu L. The utility of Enalapril treatement in anthracyclines-induced cardiac injury in children with malignancies-preliminary study. Eur Heart J. 2008;29:434.","journal-title":"Eur Heart J"},{"key":"447_CR27","doi-asserted-by":"crossref","unstructured":"Pozza A, Somigli C, Putti MC, Biffi A, Di Salvo G, Castaldi B. Early detection of cardiotoxicity in paediatric acute lymphoblastic leukaemia: the use of carvedilol in a single centre experience. Eur Heart J Supplements. 2025;27.","DOI":"10.1093\/eurheartjsupp\/suaf083.192"},{"key":"447_CR28","unstructured":"Seth R, Seth S, Bansal S, Setlur K, Gupta AK, Meena JP et al. A STUDY OF ROLE OF CARDIO PROTECTION (ACEI PLUS BETA BLOCKADE) IN EARLY CHEMOTHERAPY INDUCED CARDIOTOXICITY IN PEDIATRIC LEUKEMIA DURING CHEMOTHERAPY. Pediatr Blood Cancer. 2023;70."},{"issue":"1","key":"447_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0002-8703(95)90061-6","volume":"129","author":"RE Shaddy","year":"1995","unstructured":"Shaddy RE, Olsen SL, Bristow MR, Taylor DO, Bullock EA, Tani LY, et al. Efficacy and safety of Metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients. Am Heart J. 1995;129(1):197\u20139.","journal-title":"Am Heart J"},{"issue":"5","key":"447_CR30","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2004.06.022","volume":"22","author":"JH Silber","year":"2004","unstructured":"Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22(5):820\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"447_CR31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1017\/S1047951120003960","volume":"31","author":"S Tony","year":"2021","unstructured":"Tony S, Mevada R, Joshi N. Anthracycline-related acute cardiotoxicity in a very young Omani patient with acute myeloid leukaemia. Cardiol Young. 2021;31(3):464\u20137.","journal-title":"Cardiol Young"},{"issue":"1","key":"447_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43044-024-00506-1","volume":"76","author":"A Taghdiri","year":"2024","unstructured":"Taghdiri A. Anthracycline-induced hypertension in pediatric cancer survivors: unveiling the long-term cardiovascular risks. Egypt Heart J. 2024;76(1):1\u201312.","journal-title":"Egypt Heart J"},{"issue":"5","key":"447_CR33","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/MOP.0000000000000675","volume":"30","author":"N Bansal","year":"2018","unstructured":"Bansal N, Amdani SM, Hutchins KK, Lipshultz SE. Cardiovascular disease in survivors of childhood cancer. Curr Opin Pediatr. 2018;30(5):628\u201338.","journal-title":"Curr Opin Pediatr"},{"issue":"5","key":"447_CR34","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cvr\/cvz031","volume":"115","author":"EJ Chow","year":"2019","unstructured":"Chow EJ, Leger KJ, Bhatt NS, Mulrooney DA, Ross CJ, Aggarwal S, et al. Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. Cardiovascular Res. 2019;115(5):922.","journal-title":"Cardiovascular Res"},{"issue":"1","key":"447_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4629-6","volume":"18","author":"JC S\u00e1gi","year":"2018","unstructured":"S\u00e1gi JC, Egyed B, Kelemen A, Kutszegi N, Hegyi M, G\u00e9zsi A, et al. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. BMC Cancer. 2018;18(1):1\u201314.","journal-title":"BMC Cancer"},{"issue":"5","key":"447_CR36","first-page":"655","volume":"6","author":"M Camilli","year":"2024","unstructured":"Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM. Anthracycline cardiotoxicity in adult cancer patients: JACC: cardiooncology State-of-the-Art review. JACC: CardioOncology. 2024;6(5):655\u201377.","journal-title":"JACC: CardioOncology"},{"key":"447_CR37","unstructured":"Johnson M, Keyes D. Anthracycline toxicity. StatPearls Publishing; 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK599501\/."},{"issue":"11","key":"447_CR38","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.amjcard.2018.08.039","volume":"122","author":"B Kheiri","year":"2018","unstructured":"Kheiri B, Abdalla A, Osman M, Haykal T, Chahine A, Ahmed S, et al. Meta-Analysis of carvedilol for the prevention of Anthracycline-Induced cardiotoxicity. Am J Cardiol. 2018;122(11):1959\u201364.","journal-title":"Am J Cardiol"},{"issue":"2","key":"447_CR39","first-page":"564","volume":"21","author":"JT Li","year":"2025","unstructured":"Li JT, Duddy AM, Cardona M, Pasupuleti V, Hernandez AV. Efficacy and harms associated with \u03b2-blockers for cardiotoxicity in cancer patients undergoing chemotherapy: a systematic review and meta-analysis. Archives Med Sci. 2025;21(2):564\u201376.","journal-title":"Archives Med Sci"},{"issue":"6","key":"447_CR40","doi-asserted-by":"publisher","first-page":"H3057","DOI":"10.1152\/ajpheart.00447.2006","volume":"292","author":"GL Brower","year":"2007","unstructured":"Brower GL, Levick SP, Janicki JS. Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol. 2007;292(6):H3057\u201364.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"447_CR41","doi-asserted-by":"crossref","unstructured":"Walton M, Wagner JB. Pediatric beta blocker therapy: A comprehensive review of development and genetic variation to guide Precision-Based therapy in Children, Adolescents, and young adults. Genes. 2024;15(3).","DOI":"10.3390\/genes15030379"},{"key":"447_CR42","doi-asserted-by":"crossref","unstructured":"Austin D, Maier RH, Akhter N, Sayari M, Ogundimu E, Maddox JM, et al. Preventing cardiac damage in patients treated for breast cancer and lymphoma: the PROACT clinical trial. JACC CardioOncol. 2024;6(5):684\u201396.","DOI":"10.1016\/j.jaccao.2024.07.010"},{"key":"447_CR43","unstructured":"PROACT. Do ACE inhibitors help prevent cardiotoxicity in patients treated for breast cancer or lymphoma? - American College of Cardiology."},{"issue":"6","key":"447_CR44","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s10741-023-10328-z","volume":"28","author":"Y Gao","year":"2023","unstructured":"Gao Y, Wang R, Jiang J, Hu Y, Li H, Wang Y. ACEI\/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis. Heart Fail Rev. 2023;28(6):1405.","journal-title":"Heart Fail Rev"},{"key":"447_CR45","doi-asserted-by":"crossref","unstructured":"Ma Y, Bai F, Qin F, Li J, Liu N, Li D et al. Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: A meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2019;20(1).","DOI":"10.1186\/s40360-019-0298-6"},{"issue":"1","key":"447_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12012-019-09558-1","volume":"20","author":"L Xu","year":"2020","unstructured":"Xu L, Long Y, Tang X, Zhang N. Cardioprotective effects and duration of beta blocker therapy in Anthracycline-Treated patients: A systematic review and Meta-analysis. Cardiovasc Toxicol. 2020;20(1):11\u20139.","journal-title":"Cardiovasc Toxicol"},{"key":"447_CR47","unstructured":"Avila MS, Siqueira SRR, Waldeck L, Ayub-Ferreira SM, Takx R, Bittencourt MS et al. Renin-angiotensin system antagonists and Beta-blockers in prevention of anthracycline cardiotoxicity: a systematic review and Meta-analysis. Arquivos Brasileiros De Cardiologia. 2023;120(5)."},{"issue":"1","key":"447_CR48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cts.12857","volume":"14","author":"M Tantawy","year":"2021","unstructured":"Tantawy M, Pamittan FG, Singh S, Gong Y. Epigenetic changes associated with Anthracycline-Induced cardiotoxicity. Clin Transl Sci. 2021;14(1):36\u201346.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"447_CR49","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10741-016-9564-5","volume":"21","author":"D Mele","year":"2016","unstructured":"Mele D, Nardozza M, Spallarossa P, Frassoldati A, Tocchetti CG, Cadeddu C, et al. Current views on anthracycline cardiotoxicity. Heart Fail Rev. 2016;21(5):621\u201334.","journal-title":"Heart Fail Rev"},{"issue":"17","key":"447_CR50","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","volume":"128","author":"SE Lipshultz","year":"2013","unstructured":"Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American heart association. Circulation. 2013;128(17):1927\u201395.","journal-title":"Circulation"},{"issue":"8","key":"447_CR51","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/pbc.24505","volume":"60","author":"H Visscher","year":"2013","unstructured":"Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013;60(8):1375\u201381.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"447_CR52","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/bcp.13008","volume":"82","author":"F Aminkeng","year":"2016","unstructured":"Aminkeng F, Ross CJ, Rassekh SR, Hwang S, Rieder MJ, Bhavsar AP, et al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016;82(3):683\u201395.","journal-title":"Br J Clin Pharmacol"},{"key":"447_CR53","doi-asserted-by":"crossref","unstructured":"Reinal I, Ontoria-Oviedo I, Selva M, Casini M, Peir\u00f3-Molina E, Fambuena-Santos C et al. Modeling cardiotoxicity in pediatric oncology patients using Patient-Specific iPSC-Derived cardiomyocytes reveals downregulation of cardioprotective MicroRNAs. Antioxid (Basel Switzerland). 2023;12(7).","DOI":"10.3390\/antiox12071378"},{"key":"447_CR54","doi-asserted-by":"crossref","unstructured":"Hitawala G, Jain E, Castellanos L, Garimella R, Akku R, Chamavaliyathil AK et al. Pediatr Chemother Drugs Assoc Cardiotoxicity Cureus. 2021;13(11).","DOI":"10.7759\/cureus.19658"},{"issue":"2","key":"447_CR55","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1058-9813(98)00005-8","volume":"8","author":"JP Krischer","year":"1997","unstructured":"Krischer JP, Cuthbertson DD, Epstein S, Goorin AM, Epstein ML, Lipshultz SE. Risk factors for early anthracycline clinical cardiotoxicity in children: the pediatric oncology group experience. Prog Pediatr Cardiol. 1997;8(2):83\u201390.","journal-title":"Prog Pediatr Cardiol"},{"issue":"4","key":"447_CR56","first-page":"360","volume":"10","author":"GE Thompson","year":"2019","unstructured":"Thompson GE, Wright PP. Cardiac toxicity and anthracyclines: Mechanism, Interventions, and the trouble with troponin. J Adv Pract Oncol. 2019;10(4):360\u20136.","journal-title":"J Adv Pract Oncol"},{"issue":"3","key":"447_CR57","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/FTD.0000000000001077","volume":"45","author":"A Siemens","year":"2023","unstructured":"Siemens A, Rassekh SR, Ross CJD, Carleton BC. Development of a Dose-Adjusted polygenic risk model for Anthracycline-Induced cardiotoxicity. Ther Drug Monit. 2023;45(3):337\u201344.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"447_CR58","doi-asserted-by":"publisher","first-page":"e087343","DOI":"10.1136\/bmjopen-2024-087343","volume":"14","author":"CL Wong","year":"2024","unstructured":"Wong CL, Chan CWH, Zhang M, Cheung YT, Chow KM, Li CK, et al. Care coordination models for transition and long-term follow-up among childhood cancer survivors: a scoping review. BMJ Open. 2024;14(8):e087343\u2013e.","journal-title":"BMJ Open"},{"key":"447_CR59","doi-asserted-by":"crossref","unstructured":"Stolojanu C, Steflea R, Micsescu-Olah AM, Alexandra I, Popoiu A, Doros G. Combined utility of speckle tracking echocardiography and cardiac biomarkers for early detection of Anthracycline-Induced cardiotoxicity in pediatric oncology patients. Biomedicines. 2024;12(12).","DOI":"10.3390\/biomedicines12122849"},{"key":"447_CR60","doi-asserted-by":"crossref","unstructured":"Ardelean AM, Olariu IC, Isac R, Nalla A, Jurac R, Stolojanu C et al. Impact of cancer type and treatment protocol on cardiac function in pediatric oncology patients: an analysis utilizing speckle Tracking, global longitudinal Strain, and myocardial performance index. Diagnostics. 2023;13(17).","DOI":"10.3390\/diagnostics13172830"},{"issue":"2","key":"447_CR61","doi-asserted-by":"publisher","first-page":"58","DOI":"10.56056\/amj.2018.61","volume":"4","author":"YA Abdulqader","year":"2018","unstructured":"Abdulqader YA, Al-Ani MH, Mahmood NA. Cardiotoxicity in children with acute ieukemia treated by Anthracycline; detected by cardiac troponins and echcocardiography. Adv Med J. 2018;4(2):58\u201363.","journal-title":"Adv Med J"},{"key":"447_CR62","doi-asserted-by":"crossref","unstructured":"Tacyildiz N, Ozyoruk D, Ozelci Kavas G, Yavuz G, Unal E, Dincaslan H, et al. Selenium in the prevention of anthracycline-induced cardiac toxicity in children with cancer. J Oncol. 2012;2012:651630.","DOI":"10.1155\/2012\/651630"},{"issue":"1","key":"447_CR63","first-page":"1","volume":"13","author":"M Huo","year":"2022","unstructured":"Huo M, Tang Z, Wang L, Zhang L, Guo H, Chen Y, et al. Magnesium hexacyanoferrate nanocatalysts attenuate chemodrug-induced cardiotoxicity through an anti-apoptosis mechanism driven by modulation of ferrous iron. Nat Commun 2022. 2022;13(1):1.","journal-title":"Nat Commun 2022"},{"issue":"14","key":"447_CR64","doi-asserted-by":"publisher","first-page":"6617","DOI":"10.3390\/ijms26146617","volume":"26","author":"V Quagliariello","year":"2025","unstructured":"Quagliariello V, Berretta M, Bisceglia I, Iovine M, Barbato M, Arianna R, et al. PCSK9 inhibitor inclisiran attenuates cardiotoxicity induced by sequential anthracycline and trastuzumab exposure via NLRP3 and MyD88 pathway Inhibition. Int J Mol Sci 2025. 2025;26(14):6617.","journal-title":"Int J Mol Sci 2025"},{"key":"447_CR65","doi-asserted-by":"crossref","unstructured":"Kadeerbieke B, Wu L, Zhang YM. The role of LncRNA H19\/Hmox1 axis regulating ferroptosis in anthracycline-induced cardiotoxicity. Drug and Chemical Toxicology; 2025.","DOI":"10.1080\/01480545.2025.2503946"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00447-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00447-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00447-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:26:49Z","timestamp":1781634409000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00447-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["447"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00447-5","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}